Drug for Ulcerative Colitis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum).

The global market for Drug for Ulcerative Colitis was estimated to be worth US$ 7810 million in 2023 and is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030

Drug for Ulcerative Colitis Market Size

M= millions and B=billions

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Drug for Ulcerative Colitis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drug for Ulcerative Colitis by region & country, by Type, and by Application.

The Drug for Ulcerative Colitis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug for Ulcerative Colitis.

Market Segmentation

• Report Metric

• Details

• Report Title

• Drug for Ulcerative Colitis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Forecasted Market Size in 2030

• US$ 11250 million

• CAGR(2024-2030)

• 5.3%

• Market Size Available for Years

• 2019-2030

• Global Drug for Ulcerative Colitis Companies Covered

• Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson, Bayer, AbbVie, Eli Lilly and Company, Amgen, Takeda Pharmaceuticals Company, Ferring Pharmaceuticals, InDeX Pharmaceuticals

• Global Drug for Ulcerative Colitis Market, by Region

• North America (U.S., Canada, Mexico)

  Europe (Germany, France, UK, Italy, etc.)

  Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

  South America (Brazil, etc.)

  Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

• Global Drug for Ulcerative Colitis Market, Segment by Type

• Oral

  Injection

• Global Drug for Ulcerative Colitis Market, Segment by Application

• Hospital

  Drugs Stores

• Forecast Units

• USD million in value

• Report Coverage

• Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drug for Ulcerative Colitis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drug for Ulcerative Colitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drug for Ulcerative Colitis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Drug for Ulcerative Colitis Product Introduction
    1.2 Global Drug for Ulcerative Colitis Market Size Forecast
    1.3 Drug for Ulcerative Colitis Market Trends & Drivers
        1.3.1 Drug for Ulcerative Colitis Industry Trends
        1.3.2 Drug for Ulcerative Colitis Market Drivers & Opportunity
        1.3.3 Drug for Ulcerative Colitis Market Challenges
        1.3.4 Drug for Ulcerative Colitis Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Drug for Ulcerative Colitis Players Revenue Ranking (2023)
    2.2 Global Drug for Ulcerative Colitis Revenue by Company (2019-2024)
    2.3 Key Companies Drug for Ulcerative Colitis Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Drug for Ulcerative Colitis Product Offered
    2.5 Key Companies Time to Begin Mass Production of Drug for Ulcerative Colitis
    2.6 Drug for Ulcerative Colitis Market Competitive Analysis
        2.6.1 Drug for Ulcerative Colitis Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Drug for Ulcerative Colitis Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug for Ulcerative Colitis as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Oral
        3.1.2 Injection
    3.2 Global Drug for Ulcerative Colitis Sales Value by Type
        3.2.1 Global Drug for Ulcerative Colitis Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Drug for Ulcerative Colitis Sales Value, by Type (2019-2030)
        3.2.3 Global Drug for Ulcerative Colitis Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital
        4.1.2 Drugs Stores
    4.2 Global Drug for Ulcerative Colitis Sales Value by Application
        4.2.1 Global Drug for Ulcerative Colitis Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Drug for Ulcerative Colitis Sales Value, by Application (2019-2030)
        4.2.3 Global Drug for Ulcerative Colitis Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Drug for Ulcerative Colitis Sales Value by Region
        5.1.1 Global Drug for Ulcerative Colitis Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Drug for Ulcerative Colitis Sales Value by Region (2019-2024)
        5.1.3 Global Drug for Ulcerative Colitis Sales Value by Region (2025-2030)
        5.1.4 Global Drug for Ulcerative Colitis Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Drug for Ulcerative Colitis Sales Value, 2019-2030
        5.2.2 North America Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Drug for Ulcerative Colitis Sales Value, 2019-2030
        5.3.2 Europe Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Drug for Ulcerative Colitis Sales Value, 2019-2030
        5.4.2 Asia Pacific Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Drug for Ulcerative Colitis Sales Value, 2019-2030
        5.5.2 South America Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Drug for Ulcerative Colitis Sales Value, 2019-2030
        5.6.2 Middle East & Africa Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Drug for Ulcerative Colitis Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Drug for Ulcerative Colitis Sales Value
    6.3 United States
        6.3.1 United States Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.3.2 United States Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.4.2 Europe Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.5.2 China Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.6.2 Japan Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.7.2 South Korea Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.8.2 Southeast Asia Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Drug for Ulcerative Colitis Sales Value, 2019-2030
        6.9.2 India Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Drug for Ulcerative Colitis Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Profile
        7.1.2 Pfizer Main Business
        7.1.3 Pfizer Drug for Ulcerative Colitis Products, Services and Solutions
        7.1.4 Pfizer Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.1.5 Pfizer Recent Developments
    7.2 Novartis
        7.2.1 Novartis Profile
        7.2.2 Novartis Main Business
        7.2.3 Novartis Drug for Ulcerative Colitis Products, Services and Solutions
        7.2.4 Novartis Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.2.5 Novartis Recent Developments
    7.3 Roche
        7.3.1 Roche Profile
        7.3.2 Roche Main Business
        7.3.3 Roche Drug for Ulcerative Colitis Products, Services and Solutions
        7.3.4 Roche Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.3.5 Sanofi Recent Developments
    7.4 Sanofi
        7.4.1 Sanofi Profile
        7.4.2 Sanofi Main Business
        7.4.3 Sanofi Drug for Ulcerative Colitis Products, Services and Solutions
        7.4.4 Sanofi Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.4.5 Sanofi Recent Developments
    7.5 GSK
        7.5.1 GSK Profile
        7.5.2 GSK Main Business
        7.5.3 GSK Drug for Ulcerative Colitis Products, Services and Solutions
        7.5.4 GSK Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.5.5 GSK Recent Developments
    7.6 AstraZeneca
        7.6.1 AstraZeneca Profile
        7.6.2 AstraZeneca Main Business
        7.6.3 AstraZeneca Drug for Ulcerative Colitis Products, Services and Solutions
        7.6.4 AstraZeneca Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.6.5 AstraZeneca Recent Developments
    7.7 MSD
        7.7.1 MSD Profile
        7.7.2 MSD Main Business
        7.7.3 MSD Drug for Ulcerative Colitis Products, Services and Solutions
        7.7.4 MSD Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.7.5 MSD Recent Developments
    7.8 Johnson & Johnson
        7.8.1 Johnson & Johnson Profile
        7.8.2 Johnson & Johnson Main Business
        7.8.3 Johnson & Johnson Drug for Ulcerative Colitis Products, Services and Solutions
        7.8.4 Johnson & Johnson Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.8.5 Johnson & Johnson Recent Developments
    7.9 Bayer
        7.9.1 Bayer Profile
        7.9.2 Bayer Main Business
        7.9.3 Bayer Drug for Ulcerative Colitis Products, Services and Solutions
        7.9.4 Bayer Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.9.5 Bayer Recent Developments
    7.10 AbbVie
        7.10.1 AbbVie Profile
        7.10.2 AbbVie Main Business
        7.10.3 AbbVie Drug for Ulcerative Colitis Products, Services and Solutions
        7.10.4 AbbVie Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.10.5 AbbVie Recent Developments
    7.11 Eli Lilly and Company
        7.11.1 Eli Lilly and Company Profile
        7.11.2 Eli Lilly and Company Main Business
        7.11.3 Eli Lilly and Company Drug for Ulcerative Colitis Products, Services and Solutions
        7.11.4 Eli Lilly and Company Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.11.5 Eli Lilly and Company Recent Developments
    7.12 Amgen
        7.12.1 Amgen Profile
        7.12.2 Amgen Main Business
        7.12.3 Amgen Drug for Ulcerative Colitis Products, Services and Solutions
        7.12.4 Amgen Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.12.5 Amgen Recent Developments
    7.13 Takeda Pharmaceuticals Company
        7.13.1 Takeda Pharmaceuticals Company Profile
        7.13.2 Takeda Pharmaceuticals Company Main Business
        7.13.3 Takeda Pharmaceuticals Company Drug for Ulcerative Colitis Products, Services and Solutions
        7.13.4 Takeda Pharmaceuticals Company Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.13.5 Takeda Pharmaceuticals Company Recent Developments
    7.14 Ferring Pharmaceuticals
        7.14.1 Ferring Pharmaceuticals Profile
        7.14.2 Ferring Pharmaceuticals Main Business
        7.14.3 Ferring Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
        7.14.4 Ferring Pharmaceuticals Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.14.5 Ferring Pharmaceuticals Recent Developments
    7.15 InDeX Pharmaceuticals
        7.15.1 InDeX Pharmaceuticals Profile
        7.15.2 InDeX Pharmaceuticals Main Business
        7.15.3 InDeX Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
        7.15.4 InDeX Pharmaceuticals Drug for Ulcerative Colitis Revenue (US$ Million) & (2019-2024)
        7.15.5 InDeX Pharmaceuticals Recent Developments

 8 Industry Chain Analysis
    8.1 Drug for Ulcerative Colitis Industrial Chain
    8.2 Drug for Ulcerative Colitis Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Drug for Ulcerative Colitis Sales Model
        8.5.2 Sales Channel
        8.5.3 Drug for Ulcerative Colitis Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Drug for Ulcerative Colitis Market Trends
    Table 2. Drug for Ulcerative Colitis Market Drivers & Opportunity
    Table 3. Drug for Ulcerative Colitis Market Challenges
    Table 4. Drug for Ulcerative Colitis Market Restraints
    Table 5. Global Drug for Ulcerative Colitis Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Drug for Ulcerative Colitis Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Drug for Ulcerative Colitis Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Drug for Ulcerative Colitis Product Type
    Table 9. Key Companies Time to Begin Mass Production of Drug for Ulcerative Colitis
    Table 10. Global Drug for Ulcerative Colitis Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug for Ulcerative Colitis as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Drug for Ulcerative Colitis Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Drug for Ulcerative Colitis Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Drug for Ulcerative Colitis Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Drug for Ulcerative Colitis Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Drug for Ulcerative Colitis Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Drug for Ulcerative Colitis Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Drug for Ulcerative Colitis Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Drug for Ulcerative Colitis Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Drug for Ulcerative Colitis Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Drug for Ulcerative Colitis Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Drug for Ulcerative Colitis Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Drug for Ulcerative Colitis Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Drug for Ulcerative Colitis Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Drug for Ulcerative Colitis Sales Value by Region (2019-2024) & (%)
    Table 27. Global Drug for Ulcerative Colitis Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Drug for Ulcerative Colitis Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Drug for Ulcerative Colitis Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Drug for Ulcerative Colitis Sales Value, (2025-2030) & (US$ Million)
    Table 31. Pfizer Basic Information List
    Table 32. Pfizer Description and Business Overview
    Table 33. Pfizer Drug for Ulcerative Colitis Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Pfizer (2019-2024)
    Table 35. Pfizer Recent Developments
    Table 36. Novartis Basic Information List
    Table 37. Novartis Description and Business Overview
    Table 38. Novartis Drug for Ulcerative Colitis Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Novartis (2019-2024)
    Table 40. Novartis Recent Developments
    Table 41. Roche Basic Information List
    Table 42. Roche Description and Business Overview
    Table 43. Roche Drug for Ulcerative Colitis Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Roche (2019-2024)
    Table 45. Roche Recent Developments
    Table 46. Sanofi Basic Information List
    Table 47. Sanofi Description and Business Overview
    Table 48. Sanofi Drug for Ulcerative Colitis Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Sanofi (2019-2024)
    Table 50. Sanofi Recent Developments
    Table 51. GSK Basic Information List
    Table 52. GSK Description and Business Overview
    Table 53. GSK Drug for Ulcerative Colitis Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of GSK (2019-2024)
    Table 55. GSK Recent Developments
    Table 56. AstraZeneca Basic Information List
    Table 57. AstraZeneca Description and Business Overview
    Table 58. AstraZeneca Drug for Ulcerative Colitis Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of AstraZeneca (2019-2024)
    Table 60. AstraZeneca Recent Developments
    Table 61. MSD Basic Information List
    Table 62. MSD Description and Business Overview
    Table 63. MSD Drug for Ulcerative Colitis Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of MSD (2019-2024)
    Table 65. MSD Recent Developments
    Table 66. Johnson & Johnson Basic Information List
    Table 67. Johnson & Johnson Description and Business Overview
    Table 68. Johnson & Johnson Drug for Ulcerative Colitis Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Johnson & Johnson (2019-2024)
    Table 70. Johnson & Johnson Recent Developments
    Table 71. Bayer Basic Information List
    Table 72. Bayer Description and Business Overview
    Table 73. Bayer Drug for Ulcerative Colitis Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Bayer (2019-2024)
    Table 75. Bayer Recent Developments
    Table 76. AbbVie Basic Information List
    Table 77. AbbVie Description and Business Overview
    Table 78. AbbVie Drug for Ulcerative Colitis Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of AbbVie (2019-2024)
    Table 80. AbbVie Recent Developments
    Table 81. Eli Lilly and Company Basic Information List
    Table 82. Eli Lilly and Company Description and Business Overview
    Table 83. Eli Lilly and Company Drug for Ulcerative Colitis Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Eli Lilly and Company (2019-2024)
    Table 85. Eli Lilly and Company Recent Developments
    Table 86. Amgen Basic Information List
    Table 87. Amgen Description and Business Overview
    Table 88. Amgen Drug for Ulcerative Colitis Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Amgen (2019-2024)
    Table 90. Amgen Recent Developments
    Table 91. Takeda Pharmaceuticals Company Basic Information List
    Table 92. Takeda Pharmaceuticals Company Description and Business Overview
    Table 93. Takeda Pharmaceuticals Company Drug for Ulcerative Colitis Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Takeda Pharmaceuticals Company (2019-2024)
    Table 95. Takeda Pharmaceuticals Company Recent Developments
    Table 96. Ferring Pharmaceuticals Basic Information List
    Table 97. Ferring Pharmaceuticals Description and Business Overview
    Table 98. Ferring Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of Ferring Pharmaceuticals (2019-2024)
    Table 100. Ferring Pharmaceuticals Recent Developments
    Table 101. InDeX Pharmaceuticals Basic Information List
    Table 102. InDeX Pharmaceuticals Description and Business Overview
    Table 103. InDeX Pharmaceuticals Drug for Ulcerative Colitis Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Drug for Ulcerative Colitis Business of InDeX Pharmaceuticals (2019-2024)
    Table 105. InDeX Pharmaceuticals Recent Developments
    Table 106. Key Raw Materials Lists
    Table 107. Raw Materials Key Suppliers Lists
    Table 108. Drug for Ulcerative Colitis Downstream Customers
    Table 109. Drug for Ulcerative Colitis Distributors List
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
    Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Drug for Ulcerative Colitis Product Picture
    Figure 2. Global Drug for Ulcerative Colitis Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 4. Drug for Ulcerative Colitis Report Years Considered
    Figure 5. Global Drug for Ulcerative Colitis Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Drug for Ulcerative Colitis Revenue in 2023
    Figure 7. Drug for Ulcerative Colitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Oral Picture
    Figure 9. Injection Picture
    Figure 10. Global Drug for Ulcerative Colitis Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Drug for Ulcerative Colitis Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Hospital
    Figure 13. Product Picture of Drugs Stores
    Figure 14. Global Drug for Ulcerative Colitis Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Drug for Ulcerative Colitis Sales Value Market Share by Application, 2023 & 2030
    Figure 16. North America Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 17. North America Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    Figure 18. Europe Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 19. Europe Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    Figure 20. Asia Pacific Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 21. Asia Pacific Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    Figure 22. South America Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 23. South America Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    Figure 24. Middle East & Africa Drug for Ulcerative Colitis Sales Value (2019-2030) & (US$ Million)
    Figure 25. Middle East & Africa Drug for Ulcerative Colitis Sales Value by Country (%), 2023 VS 2030
    Figure 26. Key Countries/Regions Drug for Ulcerative Colitis Sales Value (%), (2019-2030)
    Figure 27. United States Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 28. United States Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 29. United States Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 30. Europe Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 31. Europe Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 32. Europe Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 33. China Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 34. China Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 35. China Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 36. Japan Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 37. Japan Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 38. Japan Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 39. South Korea Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 40. South Korea Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 41. South Korea Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 42. Southeast Asia Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 44. Southeast Asia Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 45. India Drug for Ulcerative Colitis Sales Value, (2019-2030) & (US$ Million)
    Figure 46. India Drug for Ulcerative Colitis Sales Value by Type (%), 2023 VS 2030
    Figure 47. India Drug for Ulcerative Colitis Sales Value by Application (%), 2023 VS 2030
    Figure 48. Drug for Ulcerative Colitis Industrial Chain
    Figure 49. Drug for Ulcerative Colitis Manufacturing Cost Structure
    Figure 50. Channels of Distribution (Direct Sales, and Distribution)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation

Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum).

The global market for Drug for Ulcerative Colitis was estimated to be worth US$ 7810 million in 2023 and is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Drug for Ulcerative Colitis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drug for Ulcerative Colitis by region & country, by Type, and by Application.

The Drug for Ulcerative Colitis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug for Ulcerative Colitis.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drug for Ulcerative Colitis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drug for Ulcerative Colitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drug for Ulcerative Colitis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.